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Abstract 
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety 
of forms, from single premature ventricular complexes to sustained ventricular tachycardia and 
fibrillation. Rapid developments have taken place over the past decade in our understanding of 
these arrhythmias and in our ability to diagnose and treat them. The field of catheter ablation 
has progressed with the development of new methods and tools, and with the publication of 
large clinical trials. Therefore, global cardiac electrophysiology professional societies undertook 
to outline recommendations and best practices for these procedures in a document that will 
update and replace the 2009 EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular 
Arrhythmias. An expert writing group, after reviewing and discussing the literature, including 
systematic review and meta-analysis, and drawing on their own experience, drafted and voted 
on recommendations and summarized current knowledge and practice in the field. Each 
recommendation is presented in knowledge byte format and is accompanied by supportive text 
and references. Further sections provide a practical synopsis of the various techniques and of 
the specific ventricular arrhythmia sites and substrates encountered in the electrophysiology 
lab. The purpose of this document is to help electrophysiologists around the world to 
appropriately select patients for catheter ablation, to perform procedures in a safe and 
efficacious manner, and to provide follow-up and adjunctive care in order to obtain the best 
possible outcomes for patients with ventricular arrhythmias. 
 
Section 1 Introduction 
1.1 Document Scope and Rationale 
The field of electrophysiology has undergone rapid progress in the last decade, with advances 
both in our understanding of the genesis of ventricular arrhythmias (VAs) and in the technology 
used to treat them. In 2009, a joint task force of the European Heart Rhythm Association (EHRA) 
and the Heart Rhythm Society (HRS), in collaboration with the American College of Cardiology 
(ACC) and the American Heart Association (AHA), produced an expert consensus document that 
outlined the state of the field and defined the indications, techniques, and outcome measures of 
VA ablation (1). In light of advances in the treatment of VAs in the interim, and the growth in the 
number of VA ablations performed in many countries and regions (2,3), an updated document is 
needed. This effort represents a worldwide partnership between transnational cardiac 
electrophysiology societies, namely, HRS, EHRA, the Asia Pacific Heart Rhythm Society (APHRS), 
and the Latin American Heart Rhythm Society (LAHRS), and collaboration with ACC, AHA, the 
Japanese Heart Rhythm Society (JHRS), the Brazilian Society of Cardiac Arrhythmias (Sociedade 
Brasileira de Arritmias Cardíacas [SOBRAC]), and the Pediatric and Congenital Electrophysiology 
Society (PACES).  
This clinical document is intended to supplement, not replace, the 2017 AHA/ACC/HRS Guideline 
for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac 
Death (4) and the 2015 European Society of Cardiology Guidelines for the Management of 
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Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (5). The 
scope of the current document relates to ablation therapy for VAs, from premature ventricular 
complexes (PVCs) to monomorphic and polymorphic ventricular tachycardia (VT) and triggers of 
ventricular fibrillation (VF). Due to its narrower scope, the consensus statement delves into 
greater detail with regard to indications and technical aspects of VA ablation than the above-
mentioned guidelines.  
Where possible, the recommendations in this document are evidence-based. It is intended to 
set reasonable standards that can be applicable worldwide, while recognizing the different 
resources, technological availability, disease prevalence, and health care delivery logistics in 
various parts of the world. In addition, parts of this document, particularly Section 9, present a 
practical guide on how to accomplish the procedures described in a manner that reflects the 
current standard of care, while recognizing that some procedures are better performed, and 
some disease states better managed, in settings in which there is specific expertise.  
References 
1. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert consensus on 
catheter ablation of ventricular arrhythmias: developed in a partnership with the European 
Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology 
(ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of 
Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009;6:886–933. 
2. Hosseini SM, Rozen G, Saleh A, et al. Catheter ablation for cardiac arrhythmias: utilization 
and in-hospital complications, 2000 to 2013. JACC Clin Electrophysiol 2017;3:1240–1248.  
3. Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, Camm J. A 
decade of information on the use of cardiac implantable electronic devices and 
interventional electrophysiological procedures in the European Society of Cardiology 
Countries: 2017 report from the European Heart Rhythm Association. Europace 
2017;19(Suppl. 2):ii1–ii90. 
4. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for 
management of patients with ventricular arrhythmias and the prevention of sudden cardiac 
death: a report of the American College of Cardiology/American Heart Association Task 
Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 
2018;15:e73–e189. 
5. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.; Task Force for the Management of 
Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the 
European Society of Cardiology (ESC). 2015 ESC guidelines for the management of patients 
with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for 
the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden 
Cardiac Death of the European Society of Cardiology (ESC). Europace 2015;17:1601–1687. 
1.2 Methods 
The writing group was selected according to each society’s procedures, including content and 
methodology experts representing the following organizations: HRS, EHRA, APHRS, LAHRS, ACC, 
AHA, JHRS, PACES, and SOBRAC. Each partner society nominated a chair and co-chair, who did 
not have relevant relationships with industry and other entities (RWIs). In accordance with HRS 
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policies, disclosure of any RWIs was required from the writing committee members (Appendix 1) 
and from all peer reviewers (Appendix 2). Of the 38 committee members, 17 (45%) had no 
relevant RWIs. Recommendations were drafted by the members who did not have relevant 
RWIs. Members of the writing group conducted comprehensive literature searches of electronic 
databases, including Medline (via PubMed), Embase, and the Cochrane Library. Evidence tables 
(Appendix 3) were constructed to summarize the retrieved studies, with nonrandomized 
observational designs representing the predominant form of evidence. Case reports were not 
used to support recommendations. Supportive text was drafted in the “knowledge byte” format 
for each recommendation. The writing committee discussed all recommendations and the 
evidence that informed them before voting. Initial failure to reach consensus was resolved by 
subsequent discussions, revisions as needed, and re-voting. Although the consensus threshold 
was set at 67%, all recommendations were approved by at least 80% of the writing committee 
members. The mean consensus over all recommendations was 95%. A quorum of two-thirds of 
the writing committee was met for all votes (1).  
Each recommendation in this document was assigned a Class of Recommendation (COR) and a 
Level of Evidence (LOE) according to the system developed by ACC and AHA (Table 1) (2). The 
COR denotes the strength of the recommendation based on a careful assessment of the 
estimated benefits and risks; COR I indicates that the benefit of an intervention far exceeds its 
risk; COR IIa indicates that the benefit of the intervention moderately exceeds the risk; COR IIb 
indicates that the benefit may not exceed the risk; and COR III indicates that the benefit is 
equivalent to or is exceeded by the risk. The LOE reflects the quality of the evidence that 
supports the recommendation. LOE A is derived from high-quality randomized controlled trials; 
LOE B-R is derived from moderate-quality randomized controlled trials; LOE B-NR is derived from 
well-designed nonrandomized studies; LOE C-LD is derived from randomized or nonrandomized 
studies with limitations of design or execution; and LOE C-EO indicates that a recommendation 
was based on expert opinion (2).  
Unique to this consensus statement is the systematic review commissioned specifically for this 
document as part of HRS’s efforts to adopt the rigorous methodology required for guideline 
development. The systematic review was performed by an experienced evidence-based practice 
committee based at the University of Connecticut, which examined the question of VT ablation 
vs control in patients with VT and ischemic heart disease (IHD) (3). The question, in PICOT 
format, was as follows: In adults with history of sustained VT and IHD, what is the effectiveness 
and what are the detriments of catheter ablation compared with other interventions? 
Components of the PICOT were as follows: P = adults with history of sustained VT and IHD; I = 
catheter ablation; C = control (no therapy or antiarrhythmic drug [AAD]); O = outcomes of 
interest, which included 1) appropriate implantable cardioverter defibrillator (ICD) therapies 
(ICD shock or antitachycardia pacing [ATP]), 2) appropriate ICD shocks, 3) VT storm (defined as 
three shocks within 24 hours), 4) recurrent VT/VF, 5) cardiac hospitalizations, and 6) all-cause 
mortality; and T = no time restrictions.  
An industry forum was conducted to achieve a structured dialogue to address technical 
questions and to gain a better understanding of future directions and challenges. Because of the 
potential for actual or perceived bias, HRS imposes strict parameters on information sharing to 
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ensure that industry participates only in an advisory capacity and has no role in either the 
writing of the document or its review. 
The draft document underwent review by the HRS Scientific and Clinical Documents Committee 
and was approved by the writing committee. Recommendations were subject to a period of 
public comment, and the entire document underwent rigorous peer review by each of the 
participating societies and revision by the Chairs, before endorsement.  
Table 1. ACC/AHA Recommendation System: Applying Class of Recommendation and Level of 
Evidence to Clinical Strategies, Interventions, Treatments, and Diagnostic Testing in Patient Care 
 
Reproduced with permission of ACC and AHA (2). 
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Section 2 Background 
This section reviews the history of VT ablation, details the mechanisms of VT, and provides 
definitions of frequently used terms (Table 2), including anatomic definitions (Table 3), as well as 
illustrating some types of sustained VA (Figure 1). 
Table 2. Definitions 
Clinical Characteristics 
Clinical ventricular tachycardia (VT): VT that has occurred spontaneously based on analysis of 
12-lead electrocardiogram (ECG) QRS morphology. 
Hemodynamically unstable VT: causes hemodynamic compromise requiring prompt 
termination. 
Idiopathic VT: used to indicate VT that is known to occur in the absence of clinically apparent 
structural heart disease (SHD). 
Idioventricular rhythm: three or more consecutive beats at a rate of up to 100 per minute 
that originate from the ventricles independent of atrial or atrioventricular (AV) nodal 
conduction. Although various arbitrary rates have been used to distinguish it from VT, the 
mechanism of ventricular rhythm is more important than the rate. Idioventricular rhythm can 
be qualified as “accelerated” when the rate exceeds 40 bpm.  
Incessant VT: continuous sustained VT that recurs promptly despite repeated intervention for 
termination over several hours. 
Nonclinical VT: VT induced by programmed electrical stimulation (PES) that has not been 
documented previously.  
Nonsustained VT: terminates spontaneously within 30 seconds. 
PVC: an early ventricular depolarization with or without mechanical contraction. We 
recommend avoiding the use of the terms “ventricular premature depolarization” and 
“premature ventricular contraction” to standardize the literature and acknowledge that early 
electrical activity does not necessarily lead to mechanical contraction. 
Presumptive clinical VT: similar to a spontaneous VT based on rate, limited ECG, or 
electrogram data available from ICD interrogation, but without the 12-lead ECG 
documentation of spontaneous VT. 
PVC burden: the amount of ventricular extrasystoles, preferably reported as the % of beats of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
ventricular origin of the total amount of beats over a 24-hour recording period.  
Repetitive monomorphic VT: continuously repeating episodes of self-terminating 
nonsustained VT. 
Sustained VT: continuous VT for 30 seconds, or which requires an intervention for 
termination (such as cardioversion). 
VT: a tachycardia (rate >100 bpm) with 3 or more consecutive beats that originates from the 
ventricles independent of atrial or AV nodal conduction. 
VT storm: three or more separate episodes of sustained VT within 24 hours, each requiring 
termination by an intervention. 
VT Morphologies 
Monomorphic VT: a similar QRS configuration from beat to beat (Figure 1A). Some variability 
in QRS morphology at initiation is not uncommon, followed by stabilization of the QRS 
morphology. 
Monomorphic VT with indeterminate QRS morphology: preferred over ventricular flutter, it 
is a term that has been applied to rapid VT that has a sinusoidal QRS configuration that 
prevents identification of the QRS morphology.  
Multiple monomorphic VTs: more than one morphologically distinct monomorphic VT, 
occurring as different episodes or induced at different times. 
Pleomorphic VT: has more than one morphologically distinct QRS complex occurring during 
the same episode of VT, but the QRS is not continuously changing (Figure 1B). 
Polymorphic VT: has a continuously changing QRS configuration from beat to beat, indicating 
a changing ventricular activation sequence (Figure 1C). 
Right bundle branch block (RBBB)- and left bundle branch block (LBBB)-like VT 
configurations: terms used to describe the dominant deflection in V1, with a dominant R-
wave described as “RBBB-like” and a dominant S-wave with a negative final component in V1 
described as “LBBB-like” configurations.  
Torsades de pointes: a form of polymorphic VT with continually varying QRS complexes that 
appear to spiral around the baseline of the ECG lead in a sinusoidal pattern. It is associated 
with QT prolongation.  
Unmappable VT: does not allow interrogation of multiple sites to define the activation 
sequence or perform entrainment mapping; this could be due to hemodynamic intolerance 
that necessitates immediate VT termination, spontaneous or pacing-induced transition to 
other morphologies of VT, or repeated termination during mapping. 
Ventricular fibrillation (VF): a chaotic rhythm defined on the surface ECG by undulations that 
are irregular in both timing and morphology, without discrete QRS complexes.  
PVC Morphologies 
Monomorphic PVC: PVCs felt reasonably to arise from the same focus. Slight changes in QRS 
morphology due to different exit sites from the same focus can be present.  
Multiple morphologies of PVC: PVCs originating from several different focal locations.   
Predominant PVC morphology: the one or more monomorphic PVC morphologies occurring 
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most frequently and serving as the target for ablation. 
Mechanisms 
Focal VT: a point source of earliest ventricular activation with a spread of activation away in 
all directions from that site. The mechanism can be automaticity, triggered activity, or 
microreentry. 
Scar-related reentry: arrhythmias that have characteristics of reentry that originate from an 
area of myocardial scar identified from electrogram characteristics or myocardial imaging. 
Large reentry circuits that can be defined over several centimeters are commonly referred to 
as “macroreentry.” 
AV = atrioventricular; ECG = electrocardiogram; LBBB = left bundle branch block; PES = programmed 
electrical stimulation; PVC = premature ventricular complex; RBBB = right bundle branch block; SHD = 
structural heart disease; VT = ventricular tachycardia. 
 
 
Figure 1. Monomorphic (A), pleomorphic (B), and polymorphic (C) VT. Reproduced with permission of the 
Heart Rhythm Society from Aliot et al. EHRA/HRS expert consensus on catheter ablation of ventricular 
arrhythmias. Heart Rhythm 2009;6:886–933. VT = ventricular tachycardia. 
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Table 3. Anatomic terminology  
Term Definition 
Right ventricular (RV) 
inflow 
The part of the RV containing the tricuspid valve, chordae, and proximal 
RV. 
RV outflow tract 
(RVOT) 
The conus or infundibulum of the RV, derived from the bulbus cordis. It 
is bounded by the supraventricular crest and the pulmonic valve. 
Tricuspid annulus Area immediately adjacent to the tricuspid valve, including septal, free-
wall, and para-Hisian regions. 
Moderator band A muscular band in the right ventricle, typically located in the mid to 
apical RV, connecting the interventricular septum to the RV free wall, 
supporting the anterior papillary muscle. It typically contains a 
subdivision of the right bundle branch (RBB).  
RV papillary muscles Three muscles connecting the RV myocardium to the tricuspid valve via 
the tricuspid chordae tendineae, usually designated as septal, posterior, 
and anterior papillary muscles. The septal papillary muscle is closely 
associated with parts of the RBB. 
Supraventricular crest Muscular ridge in the RV between the tricuspid and pulmonic valves, 
representing the boundary between the conus arteriosus and the rest 
of the RV. The exact components and terminology are controversial; 
however, some characterize it as being composed of a parietal band 
that extends from the anterior RV free wall to meet the septal band, 
which extends from the septal papillary muscle to meet it.  
Pulmonary valves The pulmonic valve includes three cusps and associated sinus, variously 
named right, left, and anterior; or anterolateral right, anterolateral left, 
and posterior sinuses. The posterior- right anterolateral commissure 
adjoins the aorta (junction of the right and left aortic sinuses). Muscle is 
present in each of the sinuses, and VA can originate from muscle fibers 
located within or extending beyond the pulmonary valve apparatus. 
Sinuses of Valsalva 
(SV), aortic cusps, 
aortic commissures 
The right (R), left (L), and noncoronary aortic valve cusps are attached 
to the respective SV. The left sinus of Valsalva (LSV) is posterior and 
leftward on the aortic root. The noncoronary sinus of Valsalva (NCSV) is 
typically the most inferior and posterior SV, located posterior and 
rightward, superior to the His bundle, and anterior and superior to the 
paraseptal region of the atria near the superior AV junctions, typically 
adjacent to atrial myocardium. The right sinus of Valsalva (RSV) is the 
most anterior cusp and may be posterior to the RVOT infundibulum. 
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VAs can also arise from muscle fibers at the commissures (connections) 
of the cusps, or from myocardium accessible to mapping and ablation 
from this location, especially from the RSV/LSV junction.  
LV outflow tract 
(LVOT) 
The aortic vestibule, composed of an infra-valvular part, bounded by 
the anterior mitral valve leaflet, but otherwise not clearly 
distinguishable from the rest of the LV; the aortic valve; and a supra-
valvular part.  
LV ostium The opening at the base of the LV to which the mitral and aortic valves 
attach.  
Aortomitral 
continuity (AMC); 
aortomitral curtain, 
or mitral-aortic 
intervalvular fibrosa 
Continuation of the anteromedial aspect of the mitral annulus to the 
aortic valve; a curtain of fibrous tissue extending from the anterior 
mitral valve leaflet to the left and noncoronary aortic cusps. The AMC is 
connected by the left and right fibrous trigones to ventricular 
myocardium, the right fibrous trigone to the membranous ventricular 
septum. 
Mitral valve annulus Area immediately adjacent to the mitral valve. This can be approached 
endocardially, or epicardially, either through the coronary venous 
system or percutaneously.  
LV papillary muscles Muscles connecting the mitral valve chordae tendineae to the LV, 
typically with posteromedial and anterolateral papillary muscles. 
Papillary muscle anatomy is variable and can have single or multiple 
heads. 
LV false tendon (or LV 
moderator band) 
A fibrous or fibromuscular chord-like band that crosses the LV cavity, 
attaching to the septum, papillary muscles, trabeculations, or free wall 
of the LV. They may contain conduction tissue and may impede 
catheter manipulation in the LV.  
Posterior-superior 
process 
The posterior-superior process of the left ventricle is the most inferior 
and posterior aspect of the basal LV, posterior to the plane of the 
tricuspid valve. VAs originating from the posterior-superior process of 
the left ventricle can be accessed from the right atrium, the LV 
endocardium, and the coronary venous system. 
Endocardium Inner lining of the heart. 
Purkinje network The specialized conduction system of the ventricles, which includes the 
His bundle, RBB and left bundle branches (LBB), and the ramifications of 
these, found in the subendocardium. The Purkinje system can generate 
focal or reentrant VTs, typically manifesting Purkinje potentials 
preceding QRS onset.  
Interventricular Muscular wall between the left and right ventricles. 
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septum 
Membranous 
ventricular septum 
The ventricular septum beneath the RSV and NCSV, through which the 
penetrating His bundle reaches the ventricular myocardium. 
LV summit Triangular region of the most superior part of the LV epicardial surface 
bounded by the left circumflex coronary artery, the left anterior 
descending artery, and an approximate line from the first septal 
coronary artery laterally to the left AV groove. The great cardiac vein 
(GCV) bisects the triangle. An area superior to the GCV is considered to 
be inaccessible to catheter ablation due to proximity of the coronary 
arteries and overlying epicardial fat.     
Crux of the heart 
(crux cordis) 
Epicardial area formed by the junction of the AV groove and posterior 
interventricular groove, at the base of the heart, approximately at the 
junction of the middle cardiac vein and coronary sinus (CS) and near the 
origin of the posterior descending coronary artery. 
Epicardium The outer layer of the heart—the visceral layer of the serous 
pericardium. 
Epicardial fat Adipose tissue variably present over the epicardial surface around 
coronary arteries, LV apex, RV free wall, left atrial appendage, right 
atrial appendage, and AV and interventricular grooves.  
Pericardial space or 
cavity 
The potential space between the parietal and visceral layers of serous 
pericardium, which normally contains a small amount of serous fluid. 
This space can be accessed for epicardial procedures.  
Parietal pericardium The layer of the serous pericardium that is attached to the inner surface 
of the fibrous pericardium and is normally apposed to the visceral 
pericardium, separated by a thin layer of pericardial fluid. 
Fibrous pericardium Thick membrane that forms the outer layer of the pericardium.  
Subxiphoid area Area inferior to the xiphoid process; typical site for percutaneous 
epicardial access. 
Phrenic nerve The right phrenic nerve lays along the right atrium and does not usually 
pass over ventricular tissue. The course of the left phrenic nerve on the 
fibrous pericardium can be quite variable and may run along the lateral 
margin of the LV near the left obtuse marginal artery and vein; inferior, 
at the base of the heart; or anterior over the sternocostal surface over 
the L main stem coronary artery or left anterior descending artery.  
Coronary sinus (CS) 
and branches 
The CS and its branches comprise the coronary venous system with the 
ostium of the CS opening into the right atrium. Tributaries of the CS, 
which runs along the left AV groove, may be used for mapping. These 
include the anterior interventricular vein (AIV), which arises at the apex 
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and runs along the anterior interventricular septum, connecting to the 
GCV that continues in the AV groove to the CS; the communicating vein 
located between aortic and pulmonary annulus; various posterior and 
lateral marginal branches or perforator veins; and the middle cardiac 
vein that typically runs along the posterior interventricular septum from 
the apex to join the CS or empty separately into the right atrium. The 
junction of the GCV and the CS is at the vein or ligament of Marshall (or 
persistent left superior vena cava, when present), and the valve of 
Vieussens (where present).   
Anatomic terminology (1–9). See also Figures 3, 4, 7, and 8. AIV = anterior interventricular vein; AMC = 
aortomitral continuity; AV = atrioventricular; CS = coronary sinus; GCV = great cardiac vein; LBB = left 
bundle branch; LSV = left sinus of Valsalva; LV = left ventricular; LVOT = left ventricular outflow tract; 
NCSV = noncoronary sinus of Valsalva; RBB = right bundle branch; RSV = right sinus of Valsalva; RV = right 
ventricular; RVOT = right ventricular outflow tract; SV = sinus of Valsalva; VA = ventricular arrhythmia; VT 
= ventricular tachycardia.   
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Section 3 Clinical Evaluation 
This section discusses clinical presentations of patients with VAs and their work-up as it pertains 
to documentation of arrhythmias and appropriate testing to assess for the presence of SHD.   
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3.1  Clinical Presentation 
Recommendation for clinical evaluation of patients with VAs 
COR LOE Recommendation References 
I C-EO 1. A careful clinical evaluation including history, physical 
examination, review of available cardiac rhythm data, prior 
imaging, and relevant laboratory work-up should be 
performed in patients presenting with VAs. 
 
 
3.2 Diagnostic Evaluation 
3.2.1 Resting 12-Lead Electrocardiogram 
Recommendations for resting 12-lead ECG 
COR LOE Recommendations References 
I B-NR 1. In patients with wide complex tachycardia, a 12-lead ECG during 
tachycardia should be obtained whenever possible. 
1–15 
I B-NR 2. In patients with suspected or documented VA, a 12-lead ECG should 
be obtained in sinus rhythm to look for evidence of underlying heart 
disease. 
16 
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3.2.2 Assessment of Structural Heart Disease and yocardial Ischemia 
Recommendations for assessment of SHD and myocardial ischemia 
COR LOE Recommendations References 
I B-NR 1. In patients with known or suspected VA, echocardiography is 
recommended for evaluation of cardiac structure and function. 
1,2 
IIa B-NR 2. In patients presenting with VA who are suspected of having 
SHD, even after normal echocardiographic evaluation, advanced 
cardiac imaging can be useful to detect and characterize 
underlying SHD.  
3–7 
IIa C-EO 3. In patients with VA in whom myocardial ischemia is suspected, 
stress testing and/or coronary angiography and subsequent 
revascularization can be beneficial before catheter ablation to 
avoid significant ischemia during induced VT.  
 
III: No 
Benefit 
B-NR 4. In patients presenting with monomorphic VT, revascularization 
alone is not effective to prevent VT recurrence. 
8–10 
References 
1. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial 
infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 
2005;352:2581–2588.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
2. Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment and survival: an analysis of 
the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2008;156:1196–
1200.  
3. Yoon Y, Ktagawa K, Kato S, et al. Prognostic value of unrecognised myocardial infarction 
detected by late gadolinium-enhanced MRI in diabetic patients with normal global and 
regional left ventricular systolic function. Eur Radiol 2013;23:2101–2108. 
4. Olivotto I, Maron M, Autore C, et al. Assessment and significance of left ventricular mass by 
cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 
2008;52:559–566.  
5. Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramural scar in patients with 
nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ 
Arrhythm Electrophysiol 2013;6:891–897. 
6. Dweck M, Abgral R, Trivieri M, et al. Hybrid magnetic resonance imaging and positron 
emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC 
Cardiovasc Imaging 2018;11:94–107. 
7. Piers SR, Tao Q, van Huls van Taxis CF, Schalij MJ, van der Geest RJ, Zeppenfeld K. Contrast-
enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic 
cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol 
2013;6:875–883.  
8. Brugada J, Aguinaga L, Mont L, Betriu A, Mulet J, Sanz G. Coronary artery revascularization in 
patients with sustained ventricular arrhythmias in the chronic phase of a myocardial 
infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol 
2001;37:529–533.  
9. Nageh M, Kim J, Chen L, Yao JF. Implantable defibrillators for secondary prevention of 
sudden cardiac death in cardiac surgery patients with perioperative ventricular arrhythmias. 
J Am Heart Assoc 2014;3:e000686. 
10. Elsokkari I, Parkash R, Gray C, et al. Effect of coronary revascularization on long-term clinical 
outcomes in patients with ischemic cardiomyopathy and recurrent ventricular arrhythmia. 
Pacing Clin Electrophysiol 2018;41:775–779. 
3.2.3 Risk Stratification in the Setting of Frequent Premature Ventricular Complexes 
Recommendations for cardiac magnetic resonance imaging (CMR) in patients with frequent PVCs 
and for PES in patients with SHD and frequent PVCs 
COR LOE Recommendations References 
IIa B-NR 1. CMR can be useful for risk stratification for sudden cardiac death in 
patients with frequent PVCs. 
1,2 
IIa C-LD 2. PES can be useful for risk stratification for sudden cardiac death in 
patients with SHD undergoing ablation of frequent PVCs. 
2 
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3.2.4 Longitudinal Follow-up in the Setting of Frequent Premature Ventricular Complexes 
Recommendation for longitudinal follow-up of patients with frequent PVCs 
COR LOE Recommendation Reference 
IIa B-NR 1. Periodic monitoring of PVC burden and LV function and 
dimensions can be useful in patients with frequent, 
asymptomatic PVCs and normal LV function and dimensions. 
1 
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Section 4 Indications for Catheter Ablation 
Following are the consensus recommendations for catheter ablation of VAs organized by 
underlying diagnosis and substrate. These recommendations are each assigned a COR and an 
LOE according to the current recommendation classification system (1). In drafting each of these 
recommendations, the writing committee took into account the published literature in the 
specific area, including the methodological quality and size of each study, as well as the 
collective clinical experience of the writing group when published data were not available. 
Implicit in each recommendation are several points: 1) the procedure is being performed by an 
electrophysiologist with appropriate training and experience in the procedure and in a facility 
with appropriate resources; 2) patient and procedural complexity vary widely, and some 
patients or situations merit a more experienced operator or a center with more capabilities than 
others, even within the same recommendation (eg, when an epicardial procedure is indicated 
and the operator or institution has limited experience with this procedure, it might be 
preferable to refer the patient to an operator or institution with adequate experience in 
performing epicardial procedures); 3) the patient is an appropriate candidate for the procedure, 
as outlined in Section 5 (Patient Selection and Preprocedural Risk Assessment), recognizing that 
the level of patient suitability for a procedure will vary widely with the clinical scenario; and 4) 
the patient’s (or designee’s) informed consent, values, and overall clinical trajectory are 
fundamental to a decision to proceed (or not) with any procedure. Therefore, in some clinical 
scenarios, initiation or continuation of medical therapy instead of an ablation procedure may be 
the most appropriate option, even when a class 1 recommendation for ablation is present. 
There may also be scenarios not explicitly covered in this document, and on which little or no 
published literature is available, in which the physician and patient must rely solely on their own 
judgment.  
Figure 2 provides an overview of care for the patient with congenital heart disease (CHD) and 
VA.  
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4.1 Idiopathic Outflow Tract Ventricular Arrhythmia 
Recommendations for catheter ablation of idiopathic outflow tract VA 
COR LOE Recommendations References 
I B-R 1. In patients with frequent and symptomatic PVCs originating 
from the RVOT in an otherwise normal heart, catheter ablation 
is recommended in preference to metoprolol or propafenone. 
1 
I B-NR 2. In patients with symptomatic VAs from the RVOT in an 
otherwise normal heart for whom antiarrhythmic medications 
are ineffective, not tolerated, or not the patient’s preference, 
catheter ablation is useful.  
 
2–12 
I B-NR 3.  In patients with symptomatic idiopathic sustained monomorphic 
VT, catheter ablation is useful.  
13–17 
IIa 
 
B-NR 4.  In patients with symptomatic VAs from the endocardial LVOT, 
including the SV, in an otherwise normal heart for whom 
antiarrhythmic medications are ineffective, not tolerated, or 
not the patient’s preference, catheter ablation can be useful.  
18–27 
IIa B-NR 5. In patients with symptomatic VAs from the epicardial outflow 
tract or LV summit in an otherwise normal heart for whom 
antiarrhythmic medications are ineffective, not tolerated, or 
not the patient’s preference, catheter ablation can be useful.  
28–32 
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4.2 Idiopathic Nonoutflow Tract Ventricular Arrhythmias 
Recommendations for catheter ablation of nonoutflow tract VAs in the absence of SHD 
COR LOE Recommendations References 
I B-NR 1. In patients with symptomatic VAs from the right ventricle at 
sites other than the OTs (tricuspid annulus, moderator band, 
parietal band, or papillary muscles) in an otherwise normal 
heart for whom antiarrhythmic medications are ineffective, 
not tolerated, or not the patient’s preference, catheter 
ablation is useful.  
1–14 
I B-NR 2. In patients with symptomatic VAs from the left ventricle at 
sites other than the outflow tracts (mitral annulus, papillary 
muscles, or aortomitral continuity) in an otherwise normal 
heart for whom antiarrhythmic medications are ineffective, 
not tolerated, or not the patient’s preference, catheter 
ablation is useful.  
15–31 
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IIa 
 
B-NR 
3. In patients with symptomatic VAs from the epicardial 
coronary venous system in an otherwise normal heart for 
whom antiarrhythmic medications are ineffective, not 
tolerated, or not the patient’s preference, catheter ablation 
can be useful. 
32–43 
IIa B-NR 4. In patients with symptomatic VAs from para-Hisian sites in 
an otherwise normal heart for whom antiarrhythmic 
medications are ineffective, not tolerated, or not the 
patient’s preference, catheter ablation can be useful.  
7,13,14,44–
49 
IIa 
 
C-LD 5. In patients with symptomatic VAs from the posterior-
superior process of the left ventricle in an otherwise normal 
heart for whom antiarrhythmic medications are ineffective, 
not tolerated, or not the patient’s preference, catheter 
ablation from the LV endocardium, right atrium, or CS, is 
useful. 
50–52 
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4.3 Premature Ventricular Complexes With or Without Left Ventricular Dysfunction   
Indications for catheter ablation of PVCs in patients with or without LV dysfunction 
COR LOE Recommendations References 
I B-NR 1. In patients with cardiomyopathy suspected to be caused by 
frequent and predominately monomorphic PVCs and for 
whom AADs are ineffective, not tolerated, or not preferred 
for long-term therapy, catheter ablation is recommended. 
1–10 
IIa B-NR 2. In patients with SHD in whom frequent PVCs are suspected 
to be contributing to a cardiomyopathy and for whom AADs 
are ineffective, not tolerated, or not preferred for long-term 
3,11,12 
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therapy, catheter ablation can be useful. 
IIa  B-NR 3. In patients with focally triggered VF refractory to AADs and 
triggered by a similar PVC, catheter ablation can be useful. 
13–17 
IIa C-LD 4. In nonresponders to cardiac resynchronization therapy with 
very frequent unifocal PVCs limiting optimal biventricular 
pacing despite pharmacological therapy, catheter ablation 
can be useful. 
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4.4 Ventricular Arrhythmia in Ischemic Heart Disease  
Recommendations for catheter ablation of VAs in patients with IHD 
COR LOE Recommendations References 
I B-R 1. In patients with IHD who experience recurrent monomorphic 
VT despite chronic amiodarone therapy, catheter ablation is 
recommended in preference to escalating AAD therapy.  
1 
I B-NR 2. In patients with IHD and recurrent symptomatic 
monomorphic VT despite AAD therapy, or when AAD therapy 
is contraindicated or not tolerated, catheter ablation is 
recommended to reduce recurrent VT. 
2–4 
I B-NR 3. In patients with IHD and VT storm refractory to AAD therapy, 
catheter ablation is recommended. 
5–9 
IIa C-EO 4. In patients with IHD and recurrent monomorphic VT, in whom 
AADs are not desired, catheter ablation can be useful. 
 
IIb A 5. In patients with IHD and an ICD who experience a first 
episode of monomorphic VT, catheter ablation may be 
considered to reduce the risk of recurrent VT or ICD 
therapies. 
10–14 
IIb C-LD 6. In patients with prior myocardial infarction and recurrent 
episodes of symptomatic sustained VT for whom prior 
endocardial catheter ablation has not been successful and who 
have ECG, endocardial mapping, or imaging evidence of a 
subepicardial VT substrate, epicardial ablation may be 
considered.  
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4.5 Nonischemic Cardiomyopathy 
Recommendations for catheter ablation of VT in nonischemic cardiomyopathy (NICM) 
COR LOE Recommendations References 
I B-NR  1. In patients with NICM and recurrent sustained monomorphic 
VT for whom antiarrhythmic medications are ineffective, 
contraindicated, or not tolerated, catheter ablation is useful for 
reducing recurrent VT and ICD shocks.  
1–6 
I  B-NR 2. In patients with NICM and electrical storm refractory to AAD 
therapy, catheter ablation is useful for reducing recurrent VT 
and ICD shocks.  
7–9 
IIa B-NR 3. In patients with NICM, epicardial catheter ablation of VT can be 
useful after failure of endocardial ablation or as the initial 
ablation approach when there is a suspicion of an epicardial 
substrate or circuit.  
4,10–13 
IIa B-NR 4. In patients with cardiac sarcoidosis and recurrent VT despite 
medical therapy, catheter ablation can be useful to reduce the 
risk of VT recurrence and ICD shocks. 
14–18 
IIa C-EO 5. In patients with NICM and recurrent sustained monomorphic 
VT for whom antiarrhythmic medications are not desired, 
catheter ablation can be useful for reducing recurrent VT and 
ICD shocks. 
 
IIb B-NR 6. In patients with NICM related to lamin A/C (LMNA) mutations 
and recurrent VT, catheter ablation may be considered as a 
palliative strategy for short-term arrhythmia control. 
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4.6 Ventricular Arrhythmia Involving the His-Purkinje System, Bundle Branch 
Reentrant Tachycardia, and Fascicular Ventricular Tachycardia 
Recommendations for catheter ablation of bundle branch reentrant tachycardia and for 
catheter ablation of fascicular VT 
COR LOE Recommendations References 
I B-NR 1. In patients with bundle-branch reentrant tachycardia, 
catheter ablation is useful for reducing the risk of recurrent 
VT. 
1–9 
I B-NR 2. In patients with idiopathic left fascicular reentrant VT for 
whom medications are ineffective, not tolerated, or not the 
patient’s preference, catheter ablation is useful.  
10–22 
 
I B-NR 3. In larger pediatric patients (≥15 kg) with idiopathic left 
fascicular reentrant VT in whom medical treatment is 
ineffective or not tolerated, catheter ablation is useful.  
23–26 
 
I B-NR 4. In patients with focal fascicular VT with or without SHD, 
catheter ablation is useful.  
11,27–29 
I B-NR 5. In patients with postinfarction reentrant Purkinje fiber-
mediated VT, catheter ablation is useful.  
30–32 
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4.7 Congenital Heart Disease 
Recommendations for catheter ablation of VA in patients with CHD 
COR LOE Recommendations References 
I B-NR 1. In patients with CHD presenting with sustained VAs, 
evaluation for potential residual anatomic or coronary 
abnormalities should be performed. 
1–6 
I B-NR 2. In patients with CHD presenting with sustained VT in the 
presence of important hemodynamic lesions, treatment of 
hemodynamic abnormalities as feasible should be performed 
in conjunction with consideration for ablation.  
2,7–16 
I B-NR 3. In patients with repaired tetralogy of Fallot and sustained 
monomorphic VT or recurrent appropriate ICD therapy for 
VAs, catheter ablation is effective.  
17–24 
IIa B-NR 4. In select patients with CHD and clinical episodes of sustained 
VT who are undergoing surgical repair of residual 
hemodynamic abnormalities, surgical ablation of VT guided 
by preoperative or intraoperative electroanatomical mapping 
can be beneficial. 
2,8,9,11,25 
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Figure 2. Congenital heart disease and sustained VT. For further discussion of ICD candidacy, please see 
PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult 
Congenital Heart Disease (14) and 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-
Based Therapy of Cardiac Rhythm Abnormalities (26). ACA = aborted cardiac arrest; CHD = congenital 
heart disease; DORV = double outlet right ventricle; ICD = implantable cardioverter defibrillator; TOF = 
tetralogy of Fallot; VT = ventricular tachycardia. 
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4.8 Inherited Arrhythmia Syndromes 
Indications for catheter ablation of VA in inherited primary arrhythmia disorders 
COR LOE Recommendations References 
I  B-NR 1. In patients with arrhythmogenic right ventricular 
cardiomyopathy (ARVC) who experience recurrent 
sustained VT or frequent appropriate ICD interventions for 
VT in whom AAD therapy is ineffective or not tolerated, 
catheter ablation, at a center with specific expertise, is 
recommended.  
1–11 
I  B-NR 2. In patients with ARVC who have failed one or more 
attempts of endocardial VT catheter ablation, an epicardial 
approach for VT ablation is recommended. 
3–7,12,13 
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IIa  B-NR 3. In patients with ARVC who experience recurrent sustained 
VT or frequent appropriate ICD interventions for VT in 
whom AAD therapy is not desired or preferred, catheter 
ablation, at a center with specific expertise, is reasonable. 
1,3–6,8 
IIa B-NR 4. In patients with Brugada syndrome who experience 
recurrent sustained VAs or frequent appropriate ICD 
interventions, catheter ablation can be useful.  
14–17 
IIa C-LD 5. In patients with ARVC, a first-line combined 
endocardial/epicardial approach for VT ablation is 
reasonable. 
1,6,12,18 
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4.9 Ventricular Arrhythmia in Hypertrophic Cardiomyopathy 
Recommendation for VA ablation in hypertrophic cardiomyopathy (HCM) 
COR LOE Recommendation References 
IIa 
 
B-NR 
 
1. In patients with HCM and recurrent monomorphic VT in 
whom AAD therapy is ineffective or not tolerated, catheter 
ablation can be useful. 
 
1–5 
References 
1. Dukkipati SR, d’Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and 
endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic 
cardiomyopathy. Circ Arrhythm Electrophysiol 2011;4:185–194. 
2. Santangeli P, Di Biase L, Lakkireddy D, et al. Radiofrequency catheter ablation of ventricular 
arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. Heart 
Rhythm 2010;7:1036–1042. 
3.  Ueda A, Fukamizu S, Soejima K, et al. Clinical and electrophysiological characteristics in 
patients with sustained monomorphic reentrant ventricular tachycardia associated with 
dilated-phase hypertrophic cardiomyopathy. Europace 2012;14:734–740. 
4.  Inada K, Seiler J, Roberts-Thomson KC, et al. Substrate characterization and catheter 
ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic 
cardiomyopathy. J Cardiovasc Electrophysiol 2011;22:41–48. 
5. Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency catheter ablation of ventricular 
tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. JACC Clin 
Electrophysiol 2018;4:339–350. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
39 
 
 
Section 5 Procedural Planning  
This section includes preprocedural risk assessment (Table 4), preprocedural patient 
preparation, and preprocedural arrhythmia documentation with a focus on the regionalizing 
information of the ECG regarding the origin of VAs (Figures 3 and 4). Furthermore, the 
capabilities of multimodality imaging in localizing the arrhythmogenic substrate are discussed in 
detail. Topics including the required equipment, personnel, and facility are detailed in this 
section. 
Table 4. The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic 
decompensation 
Variable Points 
Pulmonary disease (COPD) 5 
Age >60 3 
General anesthesia 4 
Ischemic cardiomyopathy 6 
NYHA class III/IV 6 
EF <25% 3 
VT storm 5 
Diabetes mellitus 3 
The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation, has 
values that range from 0 to 35 points (or 0 to 31 [PAINESD] when the modifiable intraprocedural variable 
“general anesthesia” is excluded) (Santangeli et al. Circ Arrhythm Electrophysiol 2015;8:68–75). COPD = 
chronic obstructive pulmonary disease; EF = ejection fraction; NYHA = New York Heart Association; VT = 
ventricular tachycardia.  
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A B 
  
Figure 3. Examples of 12-lead ECGs of premature ventricular complexes from different LV sites, as 
corroborated by successful focal ablation. (A) shows 12-lead ECG patterns of common ventricular 
arrhythmia origins in patients without SHD [1–9] from the left ventricle. All leads are displayed at the same 
amplification and sweep speed. These locations are illustrated in (B) based on 3D reconstruction of a cardiac 
computed tomography using the MUSIC software that was developed at the University of Bordeaux. The 
reconstruction shows an anterolateral view of the left ventricle, aorta, and left atrium. Also shown are the 
coronary arteries (red), the coronary venous system (blue), and the phrenic nerve (green). AIV = anterior 
interventricular vein; AL PAP = anterolateral papillary muscle; AMC = aortomitral continuity; ECG = 
electrocardiogram; GCV = great cardiac vein; ant. MA = anterior mitral valve annulus; PM PAP = 
posteromedial papillary muscle; R/L = right-left; SHD = structural heart disease; SoV = sinus of Valsalva.  
A B 
 
Figure 4. Examples of 12-lead ECGs of premature ventricular complexes from different right ventricular 
sites, as corroborated by successful focal ablation. All leads are displayed at the same amplification and 
sweep speed. (A) shows the 12-lead ECG pattern of common origins of right ventricular arrhythmias in 
patients without SHD [1–6]. The locations are detailed in a 3D reconstruction of the computed 
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tomography using the MUSIC software that was developed at the University of Bordeaux. The 
reconstruction shown in (B) illustrates the septal view of the right ventricle. Indicated are the pulmonary 
artery, the tricuspid valve annulus, and the right ventricular apex. ECGs = electrocardiograms; PA = 
pulmonary artery; RVOT= right ventricular outflow tract; SHD = structural heart disease; TVA = tricuspid 
valve annulus. 
Recommendations for preprocedural imaging for VA catheter ablation 
COR LOE Recommendations References 
I B-NR 1. In patients with LV dysfunction undergoing catheter ablation 
of VA, preprocedural or intraprocedural imaging is 
recommended to rule out cardiac thrombi.  
1–6 
IIa B-NR 2. In patients with NICM or ischemic cardiomyopathy (ICM) 
undergoing catheter ablation of VT, preprocedural CMR can 
be useful to reduce VT recurrence.  
7–9 
IIa  B-NR 3. In patients with NICM or ICM undergoing catheter ablation of 
VA, preprocedural imaging can be useful for procedural 
planning.  
10–26 
IIa C-EO 4. In patients with NICM, CMR can be useful prior to ICD 
implantation to allow imaging without device-related artifact 
for diagnostic purposes and identification of potential 
arrhythmogenic substrate.  
 
IIb C-EO 5. In patients with ICM, CMR may be considered prior to ICD 
implantation to allow imaging without device-related artifact 
for identification of the potential arrhythmogenic substrate.  
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Section 6 Intraprocedural Patient Care 
Important aspects regarding intraprocedural sedation and its potential problems are highlighted 
in this section. Furthermore, vascular access, epicardial access with its many potential 
complications are discussed in detail, as well as anticoagulation and the indications for the use 
of hemodynamic support (HS) during VT ablation procedures.  
6.1 Anesthesia 
 Recommendations for anesthesia during catheter ablation of VA 
COR LOE Recommendations References 
I C-EO 1. Provision of variable depth of sedation, analgesia, and 
anesthesia during mapping and ablation of VA is recommended.  
 
I C-EO 2. In patients undergoing VA ablation, careful preprocedural 
assessment is indicated to define the ideal strategy for sedation 
and analgesia.  
 
IIa C-LD 3. It is reasonable to avoid general anesthesia and deeper levels of 
sedation in patients with idiopathic VA, particularly if the 
arrhythmia is suspected to be catecholamine-sensitive or was 
not inducible at a prior procedure.  
1 
IIb B-NR 4. Moderate to deep sedation under close hemodynamic and 
respiratory monitoring might be considered for VA ablation in 
stable patients with idiopathic or scar-related VAs expected to 
have a longer procedure or undergo a painful technique, such 
as epicardial access.  
1–3 
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6.2 Vascular Access 
Recommendation for vascular access during catheter ablation of VA 
COR LOE Recommendation References 
I B-NR 1. Ultrasound-guided femoral arterial and venous access is 
recommended to reduce the incidence of vascular access 
complications during VA ablation.  
1–5 
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6.3 Epicardial Access 
Recommendations for epicardial access for catheter ablation 
COR LOE Recommendations References 
I C-EO 1. In patients undergoing epicardial VT ablation, imaging of the 
epicardial coronary arteries by coronary arteriography or 
coronary computed tomography angiogram prior to ablation is 
recommended to reduce the risk of arterial injury.   
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I C-EO 2. In patients undergoing epicardial VT ablation via a 
percutaneous approach, provision for immediate 
echocardiography, blood transfusion, and onsite 
cardiothoracic surgical backup is recommended. 
 
I C-EO 3. In patients with prior cardiac surgery or pericardial adhesions 
for whom epicardial VT ablation via a percutaneous approach 
is considered, careful assessment of the risk/benefit ratio and 
alternative therapies such as surgical dissection are 
recommended. 
 
I C-EO 4. In patients undergoing epicardial VT ablation, pacing with high 
stimulus intensity from the ablation electrode to rule out 
diaphragmatic stimulation is recommended to avoid phrenic 
nerve injury.  
 
6.4 Intraprocedural Hemodynamic Support 
Recommendations for catheter ablation of VA with mechanical HS 
COR LOE Recommendations References 
I C-EO 1. In select patients at risk of requiring HS, a decision to proceed 
with catheter ablation of VA should be made in collaboration 
with specialists in advanced heart failure management.  
 
IIa B-NR 2. In select patients, HS with a percutaneous ventricular assist 
device and extracorporeal membrane oxygenation during VT 
ablation can be useful to avoid acute hemodynamic 
deterioration.  
1–7 
IIb B-NR 3. Mechanical HS may be considered in selected cases to allow 
mapping and ablation of unstable VTs.  
1–6 
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6.5 Anticoagulation 
Recommendations for intraprocedural anticoagulation 
COR LOE Recommendations References 
I B-NR 1. In patients undergoing endocardial LV catheter mapping and/or 
ablation, intraprocedural systemic anticoagulation with 
intravenous heparin is recommended.  
1–6 
I C-EO 2. In patients undergoing RV endocardial mapping and/or ablation 
who are considered high risk for thromboembolism, 
intraprocedural systemic anticoagulation with intravenous heparin 
is recommended.  
 
IIa C-LD 3. In patients undergoing epicardial access after systemic 
heparinization, reversal of heparin with protamine is reasonable.  
7–8 
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Section 7 Electrophysiological Testing 
The benefits and limitations of PES are detailed in this section. 
Section 8 Mapping and Imaging Techniques 
8.1 Overview 
Activation mapping with multipolar catheters, entrainment mapping (Figures 5 and 6), and 
pacemapping are the main techniques used to map VAs. This section reviews these techniques 
including the technique of substrate mapping aiming to identify the arrhythmogenic substrate in 
sinus rhythm. Furthermore, intraprocedural imaging as it pertains to procedural safety and to 
identification of the arrhythmogenic substrate is reviewed in this section. 
 
 
Figure 5. Entrainment responses from components of reentrant VT circuit. CL = cycle length; PPI = 
postpacing interval; VT = ventricular tachycardia.    
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Figure 6. Pacing from the protected isthmus of a VT circuit. Entrainment mapping during VT. The VT CL is 
620 ms, and pacing is performed at a CL of 580 ms. A low-voltage electrogram is located in diastole on the 
recordings of the ablation catheter (Map). The stimulus-QRS interval is 230 ms and matches with the 
electrogram–QRS interval. The postpacing interval (PPI) is equal to the VT CL. The stimulus-QRS/VT CL 
ratio is 0.37, indicating that the catheter is located in the common pathway. CL = cycle length; PPI = 
postpacing interval; VT = ventricular tachycardia.      
8.2 Recommendations for Substrate Mapping in Sinus Rhythm 
Recommendations for substrate mapping in sinus rhythm 
COR LOE Recommendations References 
I B-NR 1. In patients with scar-related VT, substrate-guided ablation is 
useful for prevention of arrhythmia recurrences. 
1–11 
IIa B-NR 2. High-density multielectrode mapping to obtain a more 
comprehensive characterization of the arrhythmogenic tissue 
during catheter ablation of scar-related VT can be helpful.  
12–14 
IIa B-NR 3. In patients with no or minimal endocardial bipolar 
electrogram abnormalities, reduced unipolar voltage can be 
helpful for detection of epicardial or intramural scar.  
15–19 
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the endocardial low-voltage scar to ventricular tachycardia circuit sites and ablation 
outcomes in ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2014;25:602–608. 
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8.3 Recommendations for Intraprocedural Imaging During Catheter Ablation of Ventricular 
Arrhythmias 
Recommendations for intraprocedural imaging during catheter ablation of VAs 
COR LOE Recommendations References 
I B-NR 1. Coronary angiography or intracardiac echocardiography (ICE) is 
recommended to localize the ostia of the coronary arteries 
prior to ablation within the sinuses of Valsalva.  
1–4 
I B-NR 2. Coronary angiography is recommended to identify the course 
of the coronary arteries when ablation is performed in the 
coronary venous system or in the epicardium. 
5–8 
I B-NR 3. ICE is beneficial to identify and target the papillary muscles with 
ablation and to assess for catheter stability.  
9–20 
I B-NR 4. ICE or transthoracic echocardiography is useful to assess for 
pericardial effusion in case of hemodynamic deterioration of 
the patient.  
21–23 
I C-LD 5. ICE is useful for early recognition of complications, including 
pericardial effusion.  
21–23 
IIb B-NR 6. ICE may be useful as an adjuvant technique to identify wall 
segments with wall thinning, wall motion abnormalities, and 
segments with increased echogenicity, and also to identify 
intracardiac thrombi.  
24,25 
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8.4 Electroanatomic Mapping Systems and Robotic Navigation 
Recommendations for the use of electroanatomic mapping (EAM) systems and remote 
navigation in ablation procedures for VAs 
COR LOE Recommendations References 
I B-NR 1. In patients with VA due to SHD undergoing an ablation 
procedure, EAM is useful. 
1–9 
IIa B-NR 2. In patients with idiopathic VA undergoing an ablation 
procedure, EAM can be useful. 
4,6 
IIa B-NR 3. In patients undergoing an ablation procedure for VA, magnetic 
catheter navigation can be useful to reduce fluoroscopy use. 
10–14 
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Section 9 Mapping and Ablation 
This section is designed as a “how-to” section that details the procedural steps of VT ablation in 
different patient populations ranging from ablation of PVCs in patients without heart disease to 
ablation of VT/VF in patients with different types of SHD (Figures 7–12 and Tables 5–7). Bullet 
points summarize the key points in this section. 
9.1 Ablation Power Sources and Techniques 
Key Points 
• An impedance drop ≥10 ohms or a contact force ≥10 g is commonly used as a target for RF 
energy delivery. 
• The use of half normal saline generates larger ablation lesions but can result in steam pops. 
• Simultaneous bipolar or unipolar ablation can result in larger ablation lesions. 
• Cryoablation can be beneficial for achieving more stable contact on the papillary muscles. 
• Ethanol ablation can generate lesions in areas where the arrhythmogenic substrate cannot 
be otherwise reached, provided that suitable target vessels are present.  
• Stereotactic radiotherapy is an emerging alternative to ablation, requiring identification of a 
region of interest that can be targeted prior to the radiation treatment. 
9.2. Idiopathic Outflow Ventricular Arrhythmia    
Key Points 
• The RVOT, pulmonary arteries, SVs, LV epicardium and endocardium contain most of the 
outflow tract arrhythmias.  
• Activation mapping and pacemapping can be used to guide ablation in the RVOT. 
• Imaging of coronary artery ostia is essential before ablation in the aortic SVs. 
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• The LV summit is a challenging site of origin, often requiring mapping and/or ablation from 
the RVOT, LVOT, SVs, coronary venous system, and sometimes the epicardial space.  
• Deep intraseptal VA origins can be challenging to reach.  
 
 
Figure 7. Anatomical boundaries of the LV summit, with the inaccessible [1] and accessible [2] parts. 
Shown are the left anterior descending artery (LAD), the circumflex artery (Cx), the great cardiac vein 
(GCV), the anterior interventricular vein (AIV) and the first and second diagaonal branch of the LAD (D1, 
D2). 
9.3 Nonoutflow Idiopathic Ventricular Arrhythmias 
Key Points 
• VAs originating from the papillary muscles can be challenging due to multiple morphologies 
of the VA and the difficulty in achieving and maintaining sufficient contact during ablation. 
• VAs occur in LV papillary muscles more often than in RV papillary muscles, are more often 
posteromedial than anterolateral, and occur more often at the tip than at the base. 
• Pace mapping is less accurate than in other focal VAs. 
• ICE is particularly useful for assessing contact and stability. 
• Cryoablation can also aid in catheter stability during lesion delivery. 
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Figure 8. Intraprocedural imaging during ablation of papillary muscle arrhythmias. (A): Anatomical map of 
the left ventricle (Carto, Biosense Webster) showing contact of the ablation catheter (Abl) with the 
posteromedial papillary muscle (PMPAP). (B): Intracardiac echocardiogram showing real-time visualization 
of the ablation catheter during ablation on the anterolateral papillary muscle (ALPAP). 
9.4 Bundle Branch Reentry Ventricular Tachycardia and Fascicular Ventricular 
Tachycardia 
Key Points 
• Bundle branch reentry can occur in a variety of patients in whom the conduction system can 
be affected, including patients with dilated cardiomyopathy (DCM), valvular heart disease, 
myocardial infarction, myotonic dystrophy, Brugada syndrome, and ARVC, among others. 
• Ablation of either the right or left bundle branch eliminates bundle branch reentry 
ventricular tachycardia (BBRVT) but does not eliminate other arrhythmic substrates. 
• A correct diagnosis of BBRVT is crucial and should employ established criteria prior to 
ablation of either of the bundle branches. 
• Ablation of the AV node does not cure BBRVT. 
• Ablation of either bundle branch does not cure interfascicular VT. 
• For posterior fascicular VTs, the P1 potential is targeted during VT; if P1 cannot be identified 
or VT is not tolerated, an anatomical approach can be employed. 
• Purkinje fibers can extend to the papillary muscles, and these can be part of the VT circuit.  
• For anterior fascicular VTs, the P1 potential is targeted with ablation. 
• Focal nonreentrant fascicular VT is infrequent and can occur in patients with IHD; however, 
it cannot be induced with programmed stimulation, and the target is the earliest Purkinje 
potential during VT. 
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Table 5. Types of bundle branch reentry tachycardia 
 Type A 
Type B 
(Interfascicular tachycardia) 
Type C 
ECG morphology LBBB pattern RBBB pattern RBBB pattern 
Anterograde limb RBB LAF or LPF LBB 
Retrograde limb LBB LPF or LAF RBB 
LAF = left anterior fascicle; LBB = left bundle branch; LBBB = left bundle branch block; LPF = left posterior 
fascicle; RBB = right bundle branch; RBBB = right bundle branch block. 
Table 6. Fascicular ventricular tachycardias 
VT = ventricular tachycardia. 
9.5 Postinfarction Ventricular Tachycardia 
Key Points 
• In cases of multiple inducible VTs, the clinical VT should be targeted first. 
• Elimination of all inducible VTs reduces VT recurrence and is associated with prolonged 
arrhythmia-free survival in a number of observational studies. 
• For tolerated VTs, entrainment mapping allows for focal ablation of the critical isthmus. 
• For nontolerated VTs, various ablation strategies have been described, including targeting 
abnormal potentials, matching pace mapping sites, areas of slow conduction, linear lesions, 
and scar homogenization. 
• Imaging can be beneficial in identifying the arrhythmogenic substrate. 
I. Verapamil-sensitive fascicular reentrant VT 
1. Left posterior type 
 i.  Left posterior septal fascicular reentrant VT 
 ii.  Left posterior papillary muscle fascicular reentrant VT 
 2. Left anterior type 
 i.  Left anterior septal fascicular reentrant VT 
 ii.  Left anterior papillary muscle fascicular reentrant VT 
 3. Upper septal type 
II. Nonreentrant fascicular VT 
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• Epicardial ablation is infrequently required, but epicardial substrate is an important reason 
for VT recurrence after VT ablation in patients with prior infarcts. 
 
Figure 9. Overview of the workflow for catheter ablation of VT in patients with IHD. Not all of these steps 
might be required, and steps can be performed in a different sequence. For instance, repeat VT induction 
can be deferred in patients with hemodynamic instability. In addition, the operator might have to adapt 
to events that arise during the case, for instance, to take advantage of spontaneous initiation of stable VT 
during substrate mapping and switch to activation mapping. IHD = ischemic heart disease; PES = 
programmed electrical stimulation; SR = sinus rhythm; VT = ventricular tachycardia. 
9.6 Dilated Cardiomyopathy 
Key Points 
• Identifying the location and extent of scarring on CMR is beneficial in procedural planning 
and has improved the outcomes of ablation in patients with DCM. 
• The ablation strategy is similar to postinfarction VT. 
• An intramural substrate is more frequently encountered in DCM than in postinfarction 
patients and requires a different ablation strategy than for patients with either epicardial or 
endocardial scarring. 
• Epicardial ablation is beneficial if the scar is located in the epicardium of the LV free wall. 
• For intramural circuits involving the septum, epicardial ablation is not beneficial. 
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• In the absence of CMR, unipolar voltage mapping has been described as a method to 
indicate a deeper-seated scar. 
 
9.7 Ventricular Tachycardia Ablation in Hypertrophic Cardiomyopathy 
Key Points 
• Polymorphic VT and VF are the most common VAs in HCM; monomorphic VT is less 
common. 
• The arrhythmogenic substrate in HCM often involves the septum but can extend to the 
epicardium, often necessitating combined endocardial and epicardial ablation procedures to 
eliminate the VT. 
• VT associated with apical aneurysms is often ablated endocardially. 
 
9.8 Brugada Syndrome 
Key Points 
• PVC-triggered VF or polymorphic VT are the most prevalent VAs that motivate device 
therapy in patients with Brugada syndrome. 
• Monomorphic VT is less frequent but can be caused by BBRVT in patients with Brugada 
syndrome. 
• The arrhythmogenic substrate is located in the RV epicardium and can be demonstrated by 
sodium channel blockers. 
• Ablation targets include fractionated prolonged electrograms on the epicardial aspect of the 
RV. 
 
Figure 10. Epicardial substrate ablation in a patient with Brugada syndrome and appropriate ICD shocks 
for VF. Image integration of a preacquired CT with the electroanatomic epicardial substrate map is shown 
in (A). Purple represents bipolar voltage >1.5 mV. Fractionated potentials (arrows) are tagged with black 
dots, and a representative example is displayed. Widespread fractionated potentials were recorded from 
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the epicardial aspect of the RVOT extending down into the basal RV body. Ablation lesions are tagged 
with red dots. Some fractionated potentials could not be ablated due to the proximity of the acute 
marginal branches of the right coronary artery. Panel (B) shows the significant transient accentuation of 
the Brugada ECG pattern during the application of radiofrequency energy at one of these sites. ICD = 
implantable cardioverter defibrillator; PA = pulmonary artery; RA = right atrium; RCA = right coronary 
artery; RFA = radiofrequency ablation; RV = right ventricle.    
 
9.9 Polymorphic Ventricular Tachycardia/Ventricular Fibrillation Triggers 
Key Points 
• Recurrent PVC-induced VF is most often triggered by PVCs originating from Purkinje fibers, 
located in the RVOT, the moderator band, or the LV.  
• Patients with a single triggering PVC are better ablation candidates; however, there are 
often multiple triggers. 
• Patients with healed myocardial infarction often require extensive ablation of the Purkinje 
fiber system within or at the scar border. 
• Ischemia should be ruled out as a trigger for VF prior to ablation. 
 
9.10 Arrhythmogenic Right Ventricular Cardiomyopathy 
Key Points 
• The arrhythmogenic substrate in ARVC is located in the epicardium and can involve the 
endocardium in advanced stages. 
• The most commonly affected areas are the subtricuspid and RV outflow regions.  
• LV involvement is not uncommon. 
• Endocardial-epicardial ablation is often required and results in higher acute success and 
lower recurrence rates compared with endocardial ablation alone. 
• Conventional mapping and ablation techniques, including entrainment mapping of tolerated 
VT, pacemapping, and substrate ablation, are used.  
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Figure 11. Right ventricular voltage maps from cases of moderate (upper row) and advanced (lower row) 
arrhythmogenic right ventricular cardiomyopathy (ARVC) are shown. Purple represents a voltage >1.5 mV 
in the bipolar maps (left and right) and >5.5 mV in the unipolar maps (center); red represents a voltage 
<0.5 mV in the bipolar maps and <3.5 mV in the unipolar maps. Moderate ARVC is defined as having a 
bipolar/unipolar low-voltage area ratio of <0.23 and is associated with epicardial arrhythmogenic 
substrate area (ASA) (defined by the presence of electrograms with delayed components of >10 cm
2
. 
Advanced ARVC displays a bipolar/unipolar endocardial low-voltage area of ≥0.23, which is associated 
with an epicardial arrhythmogenic substrate area of ≤10 cm
2
. Adapted with permission from Oxford 
University Press (from Berruezo et al. Europace 2017;19:607–616). 
 
9.11 Mapping and Ablation in Congenital Heart Disease 
Key Points 
• Patients with a VT substrate after congenital heart defect surgery include those with 
repaired tetrology of Fallot, repaired ventricular septal defect, and repaired d-transposition 
of great arteries (D-TGA), as well as Ebstein’s anomaly among other disease processes. 
• VT isthmuses are often located between anatomical barriers and surgical incisions or patch 
material. 
• An anatomical isthmus can be identified and targeted during sinus rhythm.  
• For tolerated VTs, entrainment mapping is the method of choice for identifying critical 
components of the reentry circuit. 
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Figure 12. Anatomic isthmuses (AI) in repaired tetralogy of Fallot according to the surgical approach and 
variation of the malformation. RV = right ventricular; TA = tricuspid annulus; VSD = ventricular septal 
defect. 
 
9.12 Sarcoidosis         
Key Points 
• The arrhythmogenic substrate in cardiac sarcoidosis is often intramurally located but can 
include the endocardium and epicardium. 
• A CMR is beneficial in planning an ablation procedure in cardiac sarcoidosis. 
• The arrhythmogenic substrate can be complex and can include areas of active inflammation 
and chronic scarring. 
• The VT recurrence rate after ablation is high. 
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Table 7. Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis 
N LVEF, 
% 
Concurrent 
immunosuppressive 
therapy, n (%) 
VTs 
induced, 
mean±SD 
Mapping, 
Endo n/ 
Epi n  
Ablation, 
Endo n/ 
Epi n 
Patients 
undergoing 
repeated 
procedures, 
n (%) 
VT Recurrence 
n (%) 
VT Burden 
decrease, 
n (%) 
Major 
complications 
Follow-up, 
months 
Koplan et 
al.  
8 35±15 5 (63) 4±2 6/2 8/2 1 (13) 
 
6 (75) 4 (44) NR 6 
Jefic et al.  9 42±14 8 (89) 5±7 8/1 NR 3 (33) 4 (44) 9 (100) NR 20 
Naruse et 
al.  
14 40±12 12 (86) 3±1 14/0 14/0 4 (29) 6 (43) NR NR 33 
Dechering 
et al.  
8 36±19 NR 4±2 NR NR NR 1 (13) 7 (88) NR 6 
Kumar et 
al.  
21 36±14 12 (57) Median 3 
(range 1–8) 
21/8 21/5 11 (52) 15 (71) 16 (76) 4.7% 24 
Muser et 
al.  
31 42±15 22 (71) Median 3 
(range 1–5) 
31/11 31/8 9 (29) 16 (52) 28 (90) 4.5% 30 
N = number; NR = not reported.
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9.13 Chagas Disease 
Key Points 
• The pathogenesis of Chagas disease is poorly understood but often results in an inferolateral LV 
aneurysm. 
• The arrhythmogenic substrate is located intramurally and on the epicardial surface, often 
necessitating an epicardial ablation procedure. 
9.14 Miscellaneous Diseases and Clinical Scenarios with Ventricular Tachycardia 
Key Points 
• Lamin cardiomyopathy often has a poor prognosis, progressing to end-stage heart failure. 
• VT ablation is challenging due to intramural substrates. 
• VT recurrence rate is high after ablations. 
• VT in patients with noncompaction tends to originate from regions of noncompacted myocardium 
where scar can be identified in the midapical LV. 
• VT ablation in patients with left ventricular assist device can be challenging due to the limitation of 
preprocedural imaging: the electromagnetic noise generated by the left ventricular assist device. 
9.15 Surgical Therapy  
Key Points 
• Surgery-facilitated access to the epicardium via a limited subxiphoid incision can be helpful in the 
case of adhesions. 
• Cryoablation via thoracotomy is possible for posterolateral substrates and via sternotomy for 
anterior substrates. 
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9.16 Sympathetic Modulation  
Key Points 
• Sympathetic modulation targeting the stellate ganglia by video-assisted thoracoscopy may be 
considered for failed VT ablation procedures or VF storms. 
• A temporary effect can be obtained with the percutaneous injection or infusion of local anesthetics. 
9.17 Endpoints of Catheter Ablation of Ventricular Tachycardia 
Key Points 
• Noninducibility of VT by PES after ablation is a reasonable endpoint and predictor for VT recurrence 
after VT ablation in patients with SHD. 
• Due to the limitations of programmed stimulation, endpoints other than noninducibility have been 
described, including elimination of excitability, elimination of late potentials or local abnormal 
ventricular activity, dechanneling, substrate homogenization, core isolation, image-guided ablation, 
and anatomically fixed substrate ablation.  
Section 10 Postprocedural Care 
Access-related issues, anticoagulation (Table 8), and complications (Table 9), as well as the management 
thereof, are reviewed in this section. Furthermore, assessment of outcomes and determinants of 
outcomes are detailed (Figure 13). 
10.1 Postprocedural Care: Access, Anticoagulation, Disposition  
10.1.1 Postprocedural Care: Access  
Recommendations for management of venous access sites after catheter ablation of VA 
COR LOE Recommendations References 
I A 1. Manual compression is effective in achieving hemostasis after 
venous access for VT ablation.  
1–3 
IIa B-R 2. Venous access closure using temporary purse-string or figure-of-8 
suture techniques can be useful in achieving faster hemostasis and 
earlier ambulation and reducing pain or discomfort associated with 
hemostasis compared to manual compression. 
1,2 
 
Recommendation for management of arterial access sites after catheter ablation of VA  
COR LOE Recommendation References 
I A 1. Achieving arterial access site hemostasis using either manual 
compression or a vascular closure device is recommended.  
4,5 
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Recommendations for management of epicardial access sites after catheter ablation of VA  
COR LOE Recommendations References 
I C-EO 1. If pericardial bleeding or cardiac tamponade has occurred during 
epicardial VT ablation, a pericardial drain should be left in place until 
bleeding has resolved. 
 
IIa B-NR 2. The instillation of intrapericardial corticosteroids can be effective in 
reducing pericarditic chest pain after epicardial VT mapping or 
ablation.  
6,7 
IIa B-NR 3. To reduce pericardial pain after epicardial VT ablation, unless 
pericardial bleeding or cardiac tamponade has occurred, it is 
reasonable to remove all pericardial access sheaths at the end of the 
procedure.  
6,7 
IIb C-EO 4. Leaving a pericardial drain in place might be reasonable in patients at 
high risk for late bleeding or cardiac tamponade after epicardial VT 
ablation.  
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10.1.2 Postprocedural Care: Anticoagulation 
Recommendations for anticoagulation after VA ablation procedures 
COR LOE Recommendations References 
IIa C-LD 1. After less extensive endocardial VT ablation, treatment with 
an antiplatelet agent for a limited period of time is 
reasonable.  
1,2 
IIa C-LD 2. Heparin reversal with protamine for sheath removal after 
ablation is reasonable.  
3,4 
IIb C-LD 3. After extensive endocardial VT ablation, treatment with an 
oral anticoagulant for a limited period of time might be 
reasonable.  
1,2 
IIb C-EO 4. The use of heparin bridging after endocardial VT ablation 
may be considered but can be associated with an increased 
risk of periprocedural bleeding.  
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Table 8. Postprocedural care in prospective studies of catheter ablation of ventricular tachycardia 
Study Postprocedure 
NIPS 
AAD type AAD duration Follow-up ICD programming Anticoagulation 
postablation 
Bleeding and 
thromboembolic events 
(ablation arm) 
Calkins 
2000 (5) 
No Patients were 
continued on the type 
of antiarrhythmic 
therapy they had 
received before 
ablation. 
At least the first 3 
months after 
hospital discharge 
Evaluation at 1, 3, 6, 
9, 12, and 24 months 
after ablation 
Not specified Not specified Four of 146 (2.7%) 
stroke or TIA, 4 (2.7%) 
episodes of pericardial 
tamponade 
SMASH-VT 
2007 
(6) 
No No patient received an 
AAD (other than beta-
blockers) before the 
primary end point was 
reached. 
N/A Followed in the ICD 
clinic at 3, 6, 9, 12, 
18, and 24 months; 
echocardiography at 
3 and 12 months 
Not specified Oral anticoagulation 4–6 
weeks, aspirin if fewer 
than 5 ablation lesions 
One pericardial effusion 
without tamponade, 
managed 
conservatively; 1 deep 
venous thrombosis 
Stevenson 
2008 
(1) 
No The previously 
ineffective AAD was 
continued for the first 6 
months, after which 
time drug therapy was 
left to the discretion of 
the investigator. 
Six months, after 
which time drug 
therapy was left to 
the discretion of the 
investigator 
Echocardiogram and 
neurologist 
examination before 
and after ablation; 
office visit at 2 and 6 
months, with ICD 
interrogation where 
applicable 
Not specified Three months with 
either 325 mg/day 
aspirin or warfarin if 
ablation had been 
performed over an area 
over 3 cm in length. 
Vascular access 
complications in 4.7%. 
No thromboembolic 
complications 
Euro-VT 
2010 (7) 
No Drug management 
during follow-up was at 
the discretion of the 
investigator. 
Drug management 
during follow-up 
was at the 
discretion of the 
investigator. 
At 2, 6, and 12 
months, with ICD 
interrogation where 
applicable 
Investigators were 
encouraged to program 
ICD detection for slow 
VT for at least 20 beats 
or 10 seconds to allow 
nonsustained VT to 
terminate before 
therapy is triggered. 
Not specified No major bleeding or 
thromboembolic 
complications. 
V-TACH 
2010 (8) 
No Discouraged Discouraged Every 3 months from 
ICD implantation 
until completion of 
the study 
VF zone with a cutoff 
rate of 200–220 beats 
per minute and a VT 
zone with a cutoff CL of 
60 ms above the 
slowest documented VT 
Not specified One transient ischemic 
ST-segment elevation; 
and 1 TIA 
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and ATP followed by 
shock. 
CALYPSO 
2015 (9) 
No Discouraged Discouraged At 3 and 6 months Investigators were 
required to ensure that 
VT detection in the ICD 
is programmed at least 
10 beats below the rate 
of the slowest 
documented VT. 
At the discretion of the 
treating physician, 
anticoagulation 
recommended with 
aspirin or warfarin for 6–
12 weeks 
 
Marchlinski 
2016 (10) 
Not required Not dictated by the 
study protocol 
Not dictated by the 
study protocol 
At 6 months and at 1, 
2, and 3 years 
Not dictated by the 
study protocol 
Per clinical conditions 
and physician preference 
Cardiac perforation 
(n=1), pericardial 
effusion (n=3) 
VANISH 
2016 (11) 
No Continued 
preprocedure 
antiarrhythmic 
medications 
Not specified A 3-month office 
visit, echo, ICD check; 
a 6-month office 
visit, ICD check; 
every 6 months 
thereafter, an office 
visit, ICD check 
VT detection at 150 
bpm or with a 10–20 
bpm margin if the 
patient was known to 
have a slower VT. ATP 
was recommended in 
all zones. The protocol 
was modified to 
recommend prolonged 
arrhythmia detection 
duration for all 
patients. 
Intravenous heparin 
(without bolus) 6 hours 
after sheath removal, 
then warfarin if 
substrate-mapping 
approach used or if more 
than 10 minutes of RF 
time 
Major bleeding in 3 
patients; vascular injury 
in 3 patients; cardiac 
perforation in 2 
patients 
SMS 2017 
(12) 
No At the discretion of the 
investigator 
At the discretion of 
the investigator 
At 3, 6, 9, and 12 
months, and at 3- or 
6-month intervals 
until completion of 
the study or until 33-
month follow-up was 
reached 
VF zone at 200–220 
bpm, detection 18 of 24 
beats, shock only; VT 
zone detection at least 
16 consecutive beats, 
ATP, and shocks. Where 
VT rates were 
exclusively >220 bpm, 
VT zone at 160–180 
bpm was 
recommended; where 
VT rates were <220 
bpm, VT zone with a CL 
60 ms above the 
slowest VT was 
recommended 
Aspirin (250 mg/day) or 
warfarin as necessitated 
by the underlying heart 
disease 
Two tamponades 
requiring 
pericardiocentesis 
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AAD = antiarrhythmic dug; ATP = antitachycardia pacing; CL = cycle length; ICD = implantable 
cardioverter defibrillator; NIPS = noninvasive programmed stimulation; RF = radiofrequency; TIA 
= transient ischemic attack; VF = ventricular fibrillation; VT = ventricular tachycardia. 
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catheter ablation on implantable cardioverter-defibrillator interventions in patients with 
unstable ventricular arrhythmias and coronary artery disease: results from the multicenter 
randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol 
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10.2 Incidence and Management of Complications 
Table 9. Major complications of ventricular arrhythmia ablation in patients with structural heart 
disease 
Complication Incidence Mechanisms Presentation Prevention Treatment Ref. 
In-hospital 
mortality 
0%–3% VT recurrence, 
heart failure, 
complications of 
catheter ablation 
Not applicable  Correct electrolyte 
disturbances and 
optimize medical status 
before ablation 
 
 
— 
1,6–9 
Long-term 
mortality 
3%–35% 
(12–39 
months of 
follow-up) 
VT recurrence 
and progression 
of heart failure 
Cardiac 
nonarrhythmic 
death (heart 
failure) and VT 
recurrence  
Identification of patients 
with indication for heart 
transplantation 
 
 
— 
6–9 
Neurological 
complication 
(stroke, TIA, 
cerebral 
hemorrhage)  
0%–2.7% Emboli from left 
ventricle, aortic 
valve, or aorta; 
cerebral 
bleeding  
Focal or global 
neurological 
deficits  
Careful anticoagulation 
control; ICE can help 
detection of thrombus 
formation, and of aortic 
valve calcification; TEE to 
assess aortic arch 
Thrombolytic therapy 1,6–9 
Pericardial 
complications: 
cardiac 
tamponade, 
hemopericardium, 
pericarditis 
0%–2.7%  Catheter 
manipulation, RF 
delivery, 
epicardial 
perforation  
Abrupt or 
gradual fall in 
blood 
pressure; 
arterial line is 
recommended 
in ablation of 
complex VT 
Contact force can be 
useful, careful in RF 
delivery in perivenous 
foci and RVOT  
Pericardiocentesis; if 
necessary, surgical 
drainage, reversal 
heparin; steroids and 
colchicine in 
pericarditis 
1,6–9 
AV block 0%–1.4% Energy delivery 
near the 
conduction 
system 
Fall in blood 
pressure and 
ECG changes 
Careful monitoring when 
ablation is performed 
near the conduction 
system; consider 
cryoablation 
Pacemaker; upgrade 
to a biventricular 
pacing device might 
be necessary 
1,6–8 
Coronary artery 
damage/MI 
0.4%–1.9% Ablation near 
coronary artery, 
unintended 
coronary 
damage during 
catheter 
manipulation in 
the aortic root or 
crossing the 
aortic valve 
Acute 
coronary 
syndrome. 
Confirmation 
with coronary 
catheterization 
Limit power near 
coronary arteries and 
avoid energy delivery <5 
mm from coronary 
vessel; ICE is useful to 
visualize the coronary 
ostium 
Percutaneous 
coronary intervention 
1,6–9 
Heart 
failure/pulmonary 
edema 
0%–3% External 
irrigation, 
sympathetic 
response due to 
ablation, and VT 
induction 
Heart failure 
symptoms 
Urinary catheter and 
careful attention to fluid 
balance and diuresis, 
optimize clinical status 
before ablation, reduce 
irrigation volume if 
possible (decrease flow 
rates or use closed 
irrigation catheters) 
New/increased 
diuretics 
6–9 
Valvular injury 0%–0.7% Catheter 
manipulation, 
especially 
retrograde 
crossing the 
Acute 
cardiovascular 
collapse, new 
murmurs, 
progressive 
Careful catheter 
manipulation; ICE can be 
useful for identification of 
precise location of 
Echocardiography is 
essential in the 
diagnosis; medical 
therapy, including 
vasodilators and 
6–9 
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aortic valve and 
entrapment in 
the mitral valve; 
energy delivery 
to subvalvular 
structures, 
including 
papillary muscle 
heart failure 
symptoms 
energy delivery dobutamin before 
surgery; IABP is 
useful in acute mitral 
regurgitation and is 
contraindicated in 
aortic regurgitation 
Acute 
periprocedural 
hemodynamic 
decompensation, 
cardiogenic shock 
0%–11% Fluid 
overloading, 
general 
anesthesia, 
sustained VT 
Sustained 
hypotension 
despite 
optimized 
therapy 
Close monitoring of fluid 
infusion and 
hemodynamic status 
-Optimize medical status 
before ablation 
- pLVAD 
-Substrate mapping 
preferred, avoid VT 
induction in higher-risk 
patients  
Mechanical HS 6–10  
Vascular injury: 
hematomas, 
pseudoaneurysm, 
AV fistulae 
0%–6.9% Access to 
femoral arterial 
and catheter 
manipulation 
Groin 
hematomas, 
groin pain, fall 
in hemoglobin  
Ultrasound-guided 
access 
Ultrasound-guided 
compression, 
thrombin injection, 
and surgical closure 
1,6–9 
Overall major 
complications 
with SHD 
3.8%–11.24% 1,6–9 
Overall all 
complications 
7%–14.7% 2,7,11 
AV = atrioventricular; ECG = electrocardiogram; IABP = intra-aortic balloon pump; ICE = 
intracardiac echocardiography; LV = left ventricular; MI = myocardial infarction; pLVAD = 
percutaneous left ventricular assist device; RF = radiofrequency; RVOT = right ventricular 
outflow tract; SHD = structural heart disease; TEE = transesophageal echocardiography; TIA = 
transient ischemic attack; VT = ventricular tachycardia. 
References  
1. Palaniswamy C, Kolte D, Harikrishnan P, et al. Catheter ablation of postinfarction ventricular 
tachycardia: ten-year trends in utilization, in-hospital complications, and in-hospital 
mortality in the United States, Heart Rhythm 2014;11:2056–2063. 
2. Katz DF, Turakhia MP, Sauer WH, et al. Safety of ventricular tachycardia ablation in clinical 
practice: findings from 9699 hospital discharge records. Circ. Arrhythmia Electrophysiol 
2015;8:362–370.   
3. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation 
of idiopathic premature ventricular complexes. JACC Clin Electrophysiol 2015;1:116–123.  
4. Pothineni NV, Deshmukh A, Padmanabhan D, et al. Complication rates of ventricular 
tachycardia ablation: comparison of safety outcomes derived from administrative databases 
and clinical trials. Int J Cardiol 2015;201:529–531.  
5. Peichl P, Wichterle D, Pavlu L, Cihak R, Aldhoon B, Kautzner J. Complications of catheter 
ablation of ventricular tachycardia: a single center experience. Circ Arrhythm Electrophysiol 
2014;7:684–690.  
6. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided 
by electroanatomic mapping for recurrent ventricular tachycardia after myocardial 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
72 
 
 
infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 
2008;118:2773–2782. 
7.   Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients 
with structural heart disease using cooled radiofrequency energy: results of a prospective 
multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol 
2000;35:1905–1914. 
8. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of 
defibrillator therapy. N Engl J Med 2007;357:2657–2665. 
9. Kuck KH, Schaumann A, Eckardt L, et al.; VTACH Study Group. Catheter ablation of stable 
ventricular tachycardia before defibrillator implantation in patients with coronary heart 
disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.   
10. Santangeli P, Muser D, Zado ES, et al. Acute hemodynamic decompensation during catheter 
ablation of scar-related ventricular tachycardia: incidence, predictors, and impact on 
mortality. Circ Arrhythm Electrophysiol 2015;8:68–75. 
11. Santangeli P, Frankel DS, Tung R, et al. Early mortality after catheter ablation of ventricular 
tachycardia in patients with structural heart disease. J Am Coll Cardiol 2017;69:2105–2115. 
10.3 Hemodynamic Deterioration and Proarrhythmia 
Recommendation for echocardiography after VA ablation 
COR LOE Recommendation Reference 
I C-LD 1. Echocardiography should be performed in case of 
hemodynamic deterioration post-VT ablation to assess for 
pericardial effusion and cardiac tamponade. 
1 
References 
1. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application 
of echocardiography: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Committee on Clinical Application of 
Echocardiography). Circulation 1997;95:1686–1744. 
10.4 Follow-up of Patients Post Catheter Ablation of VT 
Recommendation for noninvasive programmed stimulation after catheter ablation of VT 
COR LOE Recommendation References 
IIa B-NR 1. Noninvasive programmed stimulation can be useful in the 
several days following VT catheter ablation to inform further 
management, including ICD programming, predicting the risk 
of VT recurrence, and/or considering a repeat VT catheter 
ablation.  
1,2 
References 
1. Frankel DS, Mountantonakis SE, Zado ES, et al. Noninvasive programmed ventricular 
stimulation early after ventricular tachycardia ablation to predict risk of late recurrence. J Am 
Coll Cardiol 2012;59:1529-1535. 
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2. Oloriz T, Baratto F, Trevisi N, et al. Defining the outcome of ventricular tachycardia ablation: 
timing and value of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 
2018;11:e005602.  
 
 
 
Figure 13. Factors influencing outcomes post VA ablation. ICD = implantable cardioverter defibrillator; 
LVAD = left ventricular assist device; VT = ventricular tachycardia. 
Section 11 Training and Institutional Requirements and Competencies 
This section contains the general training and institutional requirements with an emphasis on 
lifelong learning, professionalism, and acquisition and maintenance of knowledge and skills. In 
addition, institutional requirements for specific procedures are reviewed. 
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11.1 Training Requirements and Competencies for Catheter Ablation of Ventricular 
Arrhyhtmias 
Recommendation for training requirements and competencies for catheter ablation of VA 
COR LOE Recommendation References 
I C-EO 1. For clinical cardiac electrophysiologists who perform catheter 
ablation for VAs, appropriate advanced training and continued 
lifelong learning is recommended.   
11.2 Institutional Requirements for Catheter Ablation of Ventricular Tachycardia 
Recommendations for institutional requirements for catheter ablation of VT  
COR LOE Recommendations References 
I C-EO 1. Patients with certain underlying medical conditions and 
comorbidities undergoing complex VA ablations who are 
deemed to have increased procedural risk should undergo 
procedures in a hospital-based electrophysiology laboratory. 
 
I C-EO 2. Onsite interventional cardiology expertise is recommended for 
electrophysiology procedures requiring coronary imaging to 
delineate coronary anatomy for epicardial ablation, aortography 
to delineate coronary ostia for SV VT ablation, and need for 
placement of HS devices. 
 
I C-EO 3. Onsite cardiothoracic surgical backup is recommended for 
electrophysiology procedures requiring pericardial access due to 
the potential need for emergent sternotomy and 
cardiopulmonary bypass. 
 
I C-EO 4. Availability of anesthesia personnel is recommended for all 
patients undergoing catheter ablation of VAs.  
 
Section 12 Future Directions 
This section summarizes ongoing trials and the need for prospective evaluation of different 
clinical problems. It further reviews recent advances and limitations of various mapping 
techniques and addresses unanswered questions requiring future investigations. 
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